Efficacy and Safety of Regorafenib as Maintenance Therapy After First-line Treatment in Patients With Bone Sarcomas
Status:
Recruiting
Trial end date:
2024-10-01
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blinded, 2 arms study concerning patients with bone sarcoma
after the first line therapy.
In the first arm, patients will be treated with regorafenib for a maximum of 12 months as
maintenance therapy after first line therapy (chemotherapy and surgery), whereas in the
second arm, patients will be treated with placebo (standard of care).
The comparison between this two arms will allow to determine whether or not regorafenib is
efficient for disease control, in terms of Relapse-Free Survival improvement.